A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease (DAPA-CKD) provides further affirmation for SGLT2-inhibitor use in both diabetic and non-diabetic CKD aetiologies. This evidence concerns the gene SLC5A2 and chronic kidney disease.